Ganciclovir
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cytomegalovirus Retinitis
Conditions
Cytomegalovirus Retinitis, HIV Infections
Trial Timeline
— → —
NCT ID
NCT00000688About Ganciclovir
Ganciclovir is a phase 3 stage product being developed by Roche for Cytomegalovirus Retinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00000688. Target conditions include Cytomegalovirus Retinitis, HIV Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00000668 | Phase 1 | Completed |
| NCT00002095 | Pre-clinical | Completed |
| NCT00002015 | Pre-clinical | Completed |
| NCT00001034 | Phase 2 | Completed |
| NCT00002024 | Pre-clinical | Completed |
| NCT00002135 | Pre-clinical | Completed |
| NCT00002025 | Pre-clinical | Completed |
| NCT00002330 | Pre-clinical | Completed |
| NCT00002251 | Pre-clinical | Completed |
| NCT00002273 | Pre-clinical | Completed |
| NCT00002247 | Pre-clinical | Completed |
| NCT00002134 | Pre-clinical | Completed |
| NCT00002257 | Pre-clinical | Completed |
| NCT00000688 | Phase 3 | Completed |
Competing Products
20 competing products in Cytomegalovirus Retinitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP0113 + Placebo | Astellas Pharma | Phase 2 | 52 |
| ASP0113 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Letermovir oral granules + Letermovir tablet + Letermovir intravenous | Merck | Phase 2 | 52 |
| Letermovir 240 mg Oral Tablet | Merck | Phase 2 | 52 |
| Letermovir tablet + Letermovir IV | Merck | Phase 3 | 77 |
| Letermovir | Merck | Phase 1 | 33 |
| Letermovir | Merck | Approved | 85 |
| Letermovir 480 MG [Prevymis] | Merck | Phase 2 | 52 |
| V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID | Merck | Phase 1 | 33 |
| Ganciclovir | Merck | Pre-clinical | 23 |
| Letermovir + Placebo | Merck | Phase 3 | 77 |
| Letermovir | Merck | Phase 2 | 52 |
| V160 + Placebo | Merck | Phase 2 | 52 |
| V160 | Merck | Phase 1 | 33 |
| Letermovir | Merck | Phase 3 | 77 |
| Letermovir | Merck | Phase 3 | 77 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 77 |
| Zidovudine + Didanosine + Ganciclovir | Roche | Phase 1 | 33 |
| Valganciclovir | Roche | Pre-clinical | 23 |
| Foscarnet sodium + Ganciclovir | Roche | Phase 1 | 33 |